JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4083 Rocilinostat (ACY-1215)
1 Citation

Target: Histone Deacetylases (HDACs)

Summary: Selective HDAC6 inhibitor

≥21.675 mg/mL
A4084 Vorinostat (SAHA, MK0683)
9 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor

insoluble in EtOH; insoluble in H2O; ≥4.41 mg/mL
A4089 Mocetinostat (MGCD0103, MG0103)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: HDAC inhibitor,isotype-selective and potent

insoluble in EtOH; insoluble in H2O; ≥19.8 mg/mL
A4090 JNJ-26481585
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Potent HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥19.2 mg/mL
A4092 CUDC-101
1 Citation

Target: Histone Deacetylases (HDACs)|EGFR|ErbB

Summary: Multitargeted HDAC inhibitor

≥21.7 mg/mL
A4094 MC1568
3 Citation

Target: Histone Deacetylases (HDACs)

Summary: Class II HDAC inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥15.7 mg/mL
A4095 Pracinostat (SB939)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: Pan-HDAC inhibitor

insoluble in H2O; ≥11.4 mg/mL
A4096 Belinostat (PXD101)
2 Citation

Target: Histone Deacetylases (HDACs)

Summary: Hydroxamate-type HDAC inhibitor

insoluble in H2O; ≥15.92 mg/mL
A4097 CUDC-907

Target: Histone Deacetylases (HDACs)|PI3K

Summary: Potent PI3K/HDAC inhibitor

≥25.45 mg/mL
A4098 PCI-24781 (CRA-024781)

Target: Histone Deacetylases (HDACs)

Summary: Pan-HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥11.75 mg/mL